C. Ghelardini et al., ANTINOCICEPTIVE AND ANTIAMNESIC PROPERTIES OF THE PRESYNAPTIC CHOLINERGIC AMPLIFIER PG-9, The Journal of pharmacology and experimental therapeutics, 284(3), 1998, pp. 806-816
The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propiona
te [(+/-)-PG-9] (10-40 mg kg(-1) s.c.; 30-60 mg kg(-1) p.o.; 10-30 mg
kg(-1) i.v.; 10-30 mu g/mouse i.c.v.) was examined in mice, rats and g
uinea pigs by use of the hot-plate, abdominal-constriction, tail-flick
and paw-pressure tests. (+/-)-PG-9 antinociception peaked 15 min afte
r injection and then slowly diminished. The antinociception produced b
y (+/-)-PG-9 was prevented by the unselective muscarinic antagonist at
ropine, the M-1-selective antagonists pirenzepine and dicyclomine and
the acetylcholine depletor hemicholinium-3, but not by the opioid anta
gonist naloxone, the gamma-aminobutyric acid, antagonist 3-aminopropyl
-diethoxy-methyl-phosphinic acid, the H-3 agonist R-(alpha)-methylhist
amine, the D-2 antagonist quinpirole, the 5-hydroxytryptamine antagoni
st 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester
hydrochloride, the 5-hydroxytryptamine(1A) antagonist ethoxyphenyl)-4-
[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines dep
letor reserpine. Based on these data, it can be postulated that (+/-)-
PG-9 exerted an antinociceptive effect mediated by a central potentiat
ion of cholinergic transmission, (+/-)-PG-9 (10-40 mg kg(-1) i.p.) was
able to prevent amnesia induced by scopolamine (1 mg kg(-1) i.p.) and
dicyclomine (2 mg kg(-1) i.p.) in the mouse passive-avoidance test. A
ffinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, deter
mined by functional studies (rabbit vas deferens for M-1, guinea pig a
trium for M-2, guinea pig ileum for M-3 and immature guinea pig uterus
for putative M-4), have shown an M-4/M-1 selectivity ratio of 10.2 th
at might be responsible for the antinociception and the antiamnesic ef
fect induced by (+/-)-PG-9 through an increase in acetylcholine extrac
ellular levels. In the antinociceptive and antiamnesic dose range, (+/
-)-PG-9 did not impair mouse performance evaluated by the rota-rod tes
t and Animex apparatus.